%0 Journal Article
%A Afshar-Oromieh, Ali
%A Haberkorn, Uwe
%A Zechmann, Christian
%A Armor, Thomas
%A Mier, Walter
%A Spohn, Fabian
%A Debus, Nils
%A Holland-Letz, Tim
%A Babich, John
%A Kratochwil, Clemens
%T Repeated PSMA-targeting radioligand therapy of metastatic prostate cancer with (131)I-MIP-1095.
%J European journal of nuclear medicine and molecular imaging
%V 44
%N 6
%@ 1619-7089
%C Heidelberg [u.a.]
%I Springer-Verl.
%M DKFZ-2017-01093
%P 950 - 959
%D 2017
%X Prostate-specific membrane antigen (PSMA)-targeting radioligand therapy (RLT) was introduced in 2011. The first report described the antitumor and side effects of a single dose. The aim of this analysis was to evaluate toxicity and antitumor activity after single and repetitive therapies.Thirty-four men with metastatic castration-resistant prostate cancer received PSMA-RLT with (131)I-MIP-1095. Twenty-three patients received a second, and three patients a third dose, timed at PSA progression after an initial response to the preceding therapy. The applied doses were separated in three groups: <3.5, 3.5-5.0 and >5.0 GBq. Antitumor and side-effects were analyzed by blood samples and other clinical data. Follow-up was conducted for up to 5 years.The best therapeutic effect was achieved by the first therapy. A PSA decline of ≥50
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:28280855
%2 pmc:PMC5397661
%R 10.1007/s00259-017-3665-9
%U https://inrepo02.dkfz.de/record/120667